Cargando…
Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004422/ https://www.ncbi.nlm.nih.gov/pubmed/31902064 http://dx.doi.org/10.1007/s12325-019-01202-2 |
| _version_ | 1783494720415072256 |
|---|---|
| author | Guan, Haijing Sheng, Yanan Guo, Wanjie Han, Sheng Shi, Luwen |
| author_facet | Guan, Haijing Sheng, Yanan Guo, Wanjie Han, Sheng Shi, Luwen |
| author_sort | Guan, Haijing |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7004422 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70044222020-02-25 Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China” Guan, Haijing Sheng, Yanan Guo, Wanjie Han, Sheng Shi, Luwen Adv Ther Letter Springer Healthcare 2020-01-04 2020 /pmc/articles/PMC7004422/ /pubmed/31902064 http://dx.doi.org/10.1007/s12325-019-01202-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Letter Guan, Haijing Sheng, Yanan Guo, Wanjie Han, Sheng Shi, Luwen Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China” |
| title | Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China” |
| title_full | Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China” |
| title_fullStr | Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China” |
| title_full_unstemmed | Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China” |
| title_short | Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China” |
| title_sort | response letter to “letter: cost-effectiveness of alectinib for patients with untreated alk-positive non-small cell lung cancer in china” |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004422/ https://www.ncbi.nlm.nih.gov/pubmed/31902064 http://dx.doi.org/10.1007/s12325-019-01202-2 |
| work_keys_str_mv | AT guanhaijing responselettertolettercosteffectivenessofalectinibforpatientswithuntreatedalkpositivenonsmallcelllungcancerinchina AT shengyanan responselettertolettercosteffectivenessofalectinibforpatientswithuntreatedalkpositivenonsmallcelllungcancerinchina AT guowanjie responselettertolettercosteffectivenessofalectinibforpatientswithuntreatedalkpositivenonsmallcelllungcancerinchina AT hansheng responselettertolettercosteffectivenessofalectinibforpatientswithuntreatedalkpositivenonsmallcelllungcancerinchina AT shiluwen responselettertolettercosteffectivenessofalectinibforpatientswithuntreatedalkpositivenonsmallcelllungcancerinchina |